Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended September 30, 2000 (First Quarter of Fiscal Year 2001)
Business Overview: The Company operates in four segments: Pharmaceutical Distribution and Provider Services, Medical-Surgical Products and Services, Pharmaceutical Technologies and Services, and Automation and Information Services. The quarter included the acquisition of Bergen Brunswig Medical Corporation (BBMC) for approximately $180 million.
Key Financial Metrics
| Metric | Q1 2001 (Sep 30, 2000) | Q1 2000 (Sep 30, 1999) |
|---|---|---|
| Total Revenue | $8,734.6 million | $6,783.7 million |
| Operating Revenue | $6,983.2 million | $5,829.3 million |
| Gross Margin | $736.4 million (10.55% of Op. Rev.) | $654.8 million (11.23% of Op. Rev.) |
| Operating Earnings | $293.0 million | $226.7 million |
| Net Earnings | $173.2 million | $122.0 million |
| Diluted EPS | $0.61 | $0.43 |
| Cash and Equivalents | $491.1 million | $185.4 million |
| Working Capital | $3.2 billion | $2.6 billion (June 30, 2000) |
| Long-term Obligations | $1,973.3 million | $1,485.8 million (June 30, 2000) |
Cash Flow Summary: Net cash used in operating activities was $265.0 million, primarily due to increases in trade receivables ($142.2 million) and inventories ($504.3 million). Net cash used in investing activities was $285.9 million, driven by acquisitions ($239.9 million). Net cash provided by financing activities was $537.4 million, largely from commercial paper issuances ($488.0 million).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 29% year-over-year, with operating revenue up 20%. Growth was driven by increased volume, price increases, new customers, and the BBMC acquisition.
- Margin Compression: Gross margin percentage decreased from 11.23% to 10.55%. This was attributed to a higher mix of lower-margin pharmaceutical distribution sales and a decrease in margins for the Automation and Information Services segment.
- Merger Costs: Merger-related costs decreased significantly to $17.3 million from $36.8 million in the prior year. The net after-tax impact on earnings was a reduction of $11.0 million (vs. $29.7 million prior year).
- Expense Management: Selling, general, and administrative (SG&A) expenses increased 9% to $426.1 million, but improved as a percentage of operating revenue (6.10% vs. 6.71%) due to economies of scale and productivity gains.
- Balance Sheet: Inventories increased by $603.1 million and trade receivables by $227.2 million compared to June 30, 2000, reflecting business volume growth and vendor margin programs.
Outlook, Risks, and Management Commentary
- Future Merger Costs: Management estimates approximately $72.7 million ($47.2 million net of tax) in additional merger-related and integration costs will be incurred in future periods, primarily fiscal 2001 and 2002.
- Capital Resources: The Company increased its commercial paper program capacity to $1.5 billion and maintains a $1.5 billion unsecured bank credit facility. A $1.0 billion shelf registration for debt and equity was declared effective in September 2000.
- Legal Contingencies: The Company is defending approximately 563 lawsuits related to natural rubber latex glove sensitization assumed from the Allegiance acquisition. While significant defense expenses are probable, the Company cannot estimate the potential loss at this time. A substantial portion of liability is expected to be covered by insurance, subject to various limitations.
- Forward-Looking Statements: The filing contains forward-looking statements regarding future results, which are subject to risks and uncertainties that could cause actual results to differ materially.
Investor Verification Checklist
- Inventory Levels: Verify the sustainability of the $603 million increase in inventory and its impact on future working capital requirements.
- Latex Litigation Exposure: Monitor updates on the 563 pending latex glove lawsuits and the status of insurance coverage negotiations with AEIA.
- Merger Integration Costs: Track the realization of the estimated $72.7 million in future merger-related costs against actual quarterly expenses.
- Margin Trends: Assess whether the decline in gross margin percentage (10.55%) is a temporary mix issue or a structural shift in the pharmaceutical distribution business.
- Debt Capacity: Confirm the utilization of the $1.5 billion commercial paper program and the $1.5 billion credit facility to ensure liquidity remains adequate for expansion.